<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00105989</url>
  </required_header>
  <id_info>
    <org_study_id>8606</org_study_id>
    <secondary_id>F1J-MC-HMDI</secondary_id>
    <nct_id>NCT00105989</nct_id>
  </id_info>
  <brief_title>Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder</brief_title>
  <official_title>Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of duloxetine compared with
      placebo in the prevention of depressive recurrences among patients with recurrent major
      depressive disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Depressive Recurrence After Time (t) in Days</measure>
    <time_frame>Every Visit from Week 34 up to Week 86 (Maintenance Phase)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence Count</measure>
    <time_frame>Every Visit from Week 35 up to Week 86 (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Greater Than or Equal to 50% Worsening After Time (t) in Days</measure>
    <time_frame>Every Visit from Week 34 up to Week 86 (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of Response at Any Time</measure>
    <time_frame>Every Visit from Week 35 up to Week 86 (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score - Acute and Continuation Phases</measure>
    <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Clinical Global Impressions (CGI) Severity Scale - Acute and Continuation Phases</measure>
    <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Clinical Global Impressions (CGI) Severity Scale - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values at Endpoint in Patient's Global Impressions of Improvement (PGI-I) - Acute and Continuation Phases</measure>
    <time_frame>Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values at Endpoint in Patient's Global Impressions of Improvement (PGI-I) - Maintenance Phase</measure>
    <time_frame>Week 86 (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Hamilton Depression Rating Scale Subscales, Including the Core, Maier, Anxiety/Somatization, Retardation/Somatization, and Sleep Subscales, and the Depressed Mood Item - Acute and Continuation Phases</measure>
    <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Hamilton Depression Rating Scale Subscales, Including the Core, Maier, Anxiety/Somatization, Retardation/Somatization, and Sleep Subscales, and the Depressed Mood Item - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Visual Analog Scales (VAS) for Pain - Acute and Continuation Phase</measure>
    <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Visual Analog Scales (VAS) for Pain - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Symptom Questionnaire-Somatic Subscale (SQ-SS) - Acute and Continuation Phases</measure>
    <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Symptom Questionnaire-Somatic Subscale (SQ-SS) - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Acute and Continuation Phases</measure>
    <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in 36-item Short-Form Health Survey (SF-36) - Acute and Continuation Phase</measure>
    <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in 36-item Short-Form Health Survey (SF-36) - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization and Hospitalization Module - Visits to Health Care Providers - Acute and Continuation Phases</measure>
    <time_frame>Week 0 through Week10 (Acute) through Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization and Hospitalization Module - Visits to Health Care Providers - Maintenance Phase</measure>
    <time_frame>Week 34 through Week 86 (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Average Number of Hours Worked in a Week - Acute and Continuation Phases</measure>
    <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Average Number of Hours Worked in a Week - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Number of Missed Paid Work Hours - Acute and Continuation Phase</measure>
    <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Number of Missed Paid Work Hours - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Males)</measure>
    <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Females)</measure>
    <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Maintenance Phase (Males)</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Maintenance Phase (Females)</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Change From Baseline to Endpoint in Weight - Acute and Continuation Phases</measure>
    <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Change From Baseline to Endpoint in Weight - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Change From Baseline to Endpoint in Pulse - Acute and Continuation Phases</measure>
    <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Change From Baseline to Endpoint in Pulse - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Change From Baseline to Endpoint in Blood Pressure - Acute and Continuation Phases</measure>
    <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Change From Baseline to Endpoint in Blood Pressure - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Albumin - Acute Phase</measure>
    <time_frame>Week 0 and Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Acute Phase</measure>
    <time_frame>Week 0 and Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Chloride - Acute Phase</measure>
    <time_frame>Week 0 and Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Eosinophils - Acute Phase</measure>
    <time_frame>Week 0 and Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Acute Phase</measure>
    <time_frame>Week 0 and Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Acute Phase</measure>
    <time_frame>Week 0 and Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hemoglobin - Acute Phase</measure>
    <time_frame>Week 0 and Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Platelet Count - Acute Phase</measure>
    <time_frame>Week 0 and Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Sodium - Acute Phase</measure>
    <time_frame>Week 0 and Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Acute Phase</measure>
    <time_frame>Week 0 and Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Uric Acid - Acute Phase</measure>
    <time_frame>Week 0 and Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Albumin - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bicarbonate, HCO3 - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bilirubin, Direct - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bilirubin, Total - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Erythrocyte Count - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hemoglobin - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Leukocyte Count - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Low Density Lipoprotein (LDL) Cholesterol (Direct) - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Hemoglobin - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Volume (MCV) - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Monocytes - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Continuation Phase</measure>
    <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Alanine Aminotransferase (ALT) - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Glucose - Maintenance Phase</measure>
    <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of Participants -- Open-Label Acute Therapy Phase</measure>
    <time_frame>Every Visit from Week 0 up to Week 10 (Acute)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of the Participants -- Open-Label Continuation Phase</measure>
    <time_frame>Every Visit from Week 10 up to Week 34 (Continuation)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">514</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <arm_group_label>A</arm_group_label>
    <other_name>LY248686</other_name>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be at least 18 years old.

          -  Patient must be diagnosed with depression and have had previous episodes of
             depression.

          -  Patient must sign informed consent.

        Exclusion Criteria:

          -  Female and pregnant or breastfeeding.

          -  History of bipolar disorder, schizophrenia, or other psychotic disorders.

          -  Suffer from a serious medical illness (other than depression) or abnormal laboratory
             result that would require a change in medication, intervention, or hospitalization.

          -  Have been treated with a medication called monoamine oxidase inhibitor (MAOI) within
             14 days of the start of the study, or potential need to use a MAOI within 5 days of
             finishing the study.

          -  Have taken an antidepressant called fluoxetine within 30 days of the start of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Angouleme</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Douai</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fains</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Roubaix</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ellwangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Village Nikolskoe</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2005</study_first_submitted>
  <study_first_submitted_qc>March 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2005</study_first_posted>
  <results_first_submitted>January 23, 2009</results_first_submitted>
  <results_first_submitted_qc>June 5, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 17, 2009</results_first_posted>
  <last_update_submitted>July 21, 2009</last_update_submitted>
  <last_update_submitted_qc>July 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The Acute - Open Label (Week 0-10) participants were reported in the Baseline Characteristics section of this results record.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Duloxetine</title>
          <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Acute - Open Label: Week 0-10</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="514"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="413"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Response Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Recurrence Criteria Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified - no reason reported</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Continuation - Open Label:Week 10-34</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="413"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="288"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Response Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Recurrence Criteria Met</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified - no reason reported</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance - Double-Blind:Week 34-86</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Response Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Recurrence Criteria Met</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified - no reason reported</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Duloxetine</title>
          <description>duloxetine 60-120 mg QD</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="514"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.6" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>17-item Hamilton Depression Rating Scale (HAMD-17) Total Score</title>
          <description>The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (absent, mild, moderate, severe, very severe) or a 3-point scale (absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.07" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at First Episode</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.16" spread="13.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impressions - Severity (CGI-S) Total Score</title>
          <description>Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.49" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Current Episode</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.02" spread="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Last Episode</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.14" spread="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.6" spread="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Previous Episodes</title>
          <units>previous episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.22" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Interval Between Episodes</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.38" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.7" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Depressive Recurrence After Time (t) in Days</title>
        <description>Recurrence: Clinical Global Impression-Severity (CGI-S) score &gt;=4 and met Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for major depressive disorder (MDD); had 3 consecutive visits where re-emergence criteria met; had total of 10 visits where re-emergence criteria was satisfied; discontinued due to lack of efficacy.</description>
        <time_frame>Every Visit from Week 34 up to Week 86 (Maintenance Phase)</time_frame>
        <population>All randomized patients. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Depressive Recurrence After Time (t) in Days</title>
          <description>Recurrence: Clinical Global Impression-Severity (CGI-S) score &gt;=4 and met Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for major depressive disorder (MDD); had 3 consecutive visits where re-emergence criteria met; had total of 10 visits where re-emergence criteria was satisfied; discontinued due to lack of efficacy.</description>
          <population>All randomized patients. Intent to Treat analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t=7 days (N=145, N=139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68"/>
                    <measurement group_id="O2" value="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=14 days (N=143, N=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37"/>
                    <measurement group_id="O2" value="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=21 days (N=141, N=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37"/>
                    <measurement group_id="O2" value="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=28 days (N=140, N=135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07"/>
                    <measurement group_id="O2" value="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=56 days (N=136, N=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19"/>
                    <measurement group_id="O2" value="12.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=84 days (N=131, N=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33"/>
                    <measurement group_id="O2" value="21.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=112 days (N=122, N=96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.58"/>
                    <measurement group_id="O2" value="25.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=140 days (N=119, N=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.34"/>
                    <measurement group_id="O2" value="28.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=168 days (N=115, N=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.89"/>
                    <measurement group_id="O2" value="28.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=196 days (N=111, N=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.69"/>
                    <measurement group_id="O2" value="28.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=224 days (N=108, N=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.50"/>
                    <measurement group_id="O2" value="29.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=252 days (N=105, N=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.32"/>
                    <measurement group_id="O2" value="32.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=280 days (N=99, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.32"/>
                    <measurement group_id="O2" value="34.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=308 days (N=96, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.32"/>
                    <measurement group_id="O2" value="34.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=336 days (N=95, N=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.23"/>
                    <measurement group_id="O2" value="34.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=364 days (N=93, N=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.03"/>
                    <measurement group_id="O2" value="35.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 257 randomized patients (randomly assigned with equal probability to the two treatment groups) were needed to have 90% power to detect 40% versus 20% recurrence rates over 52 weeks, using a log rank test at a two-sided significance level of .05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons. The primary efficacy analysis compared the time to recurrence during the maintenance phase between all duloxetine and placebo patients using the log-rank test, stratified by country at =.05.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>The log rank method provides a single p-value comparing time to depressive recurrence for placebo and duloxetine.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence Count</title>
        <description>Number of participants who experienced a depressive recurrence at any time during the double-blind maintenance therapy phase.</description>
        <time_frame>Every Visit from Week 35 up to Week 86 (Maintenance Phase)</time_frame>
        <population>Number of randomized patients with at least one non-missing postbaseline assessment during the double-blind maintenance therapy phase. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence Count</title>
          <description>Number of participants who experienced a depressive recurrence at any time during the double-blind maintenance therapy phase.</description>
          <population>Number of randomized patients with at least one non-missing postbaseline assessment during the double-blind maintenance therapy phase. Intent to Treat analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Frequencies are analyzed using Cochran-Mantel-Haenszel controlling for investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Greater Than or Equal to 50% Worsening After Time (t) in Days</title>
        <description>Worsening occurs if patient had a &gt;=50% increase from baseline on the 17-Item Hamilton Depression Rating Scale (HAMD-17) total score and a Clinical Global Impression-Severity (CGI-S) score &gt;=3 at any time during the double-blind maintenance therapy phase.</description>
        <time_frame>Every Visit from Week 34 up to Week 86 (Maintenance Phase)</time_frame>
        <population>Number of randomized patients with at least one non-missing post-baseline assessment during the double blind maintenance therapy phase. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Greater Than or Equal to 50% Worsening After Time (t) in Days</title>
          <description>Worsening occurs if patient had a &gt;=50% increase from baseline on the 17-Item Hamilton Depression Rating Scale (HAMD-17) total score and a Clinical Global Impression-Severity (CGI-S) score &gt;=3 at any time during the double-blind maintenance therapy phase.</description>
          <population>Number of randomized patients with at least one non-missing post-baseline assessment during the double blind maintenance therapy phase. Intent to Treat analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t=7 days (N=142, N=140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07"/>
                    <measurement group_id="O2" value="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=14 days (N=140, N=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45"/>
                    <measurement group_id="O2" value="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=21 days (N=136, N=130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.53"/>
                    <measurement group_id="O2" value="7.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=28 days (N=132, N=125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.63"/>
                    <measurement group_id="O2" value="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=56 days (N=124, N=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.89"/>
                    <measurement group_id="O2" value="22.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=84 days (N=114, N=88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.99"/>
                    <measurement group_id="O2" value="31.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=112 days (N=105, N=81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.48"/>
                    <measurement group_id="O2" value="35.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=140 days (N=100, N=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.02"/>
                    <measurement group_id="O2" value="40.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=168 days (N=95, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.61"/>
                    <measurement group_id="O2" value="42.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=196 days (N=93, N=67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.19"/>
                    <measurement group_id="O2" value="44.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=224 days (N=90, N=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.57"/>
                    <measurement group_id="O2" value="45.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=252 days (N=84, N=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.04"/>
                    <measurement group_id="O2" value="45.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=280 days (N=81, N=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.88"/>
                    <measurement group_id="O2" value="45.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=308 days (N=78, N=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.88"/>
                    <measurement group_id="O2" value="46.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=336 days (N=77, N=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.88"/>
                    <measurement group_id="O2" value="49.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=364 days (N=75, N=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.65"/>
                    <measurement group_id="O2" value="51.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Log Rank</method>
            <method_desc>The log rank method provides a single p-value comparing time to depressive recurrence for placebo and duloxetine.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Loss of Response at Any Time</title>
        <description>Loss of response was defined as a HAMD-17 total score &gt;9 and a CGI-Severity score &gt;2 at any one time during the double-blind maintenance phase of the study regardless of whether or not they subsequently regained response or not.</description>
        <time_frame>Every Visit from Week 35 up to Week 86 (Maintenance Phase)</time_frame>
        <population>Number of randomized patients with at least one non-missing post-baseline assessment during the double-blind maintenance therapy phase. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Loss of Response at Any Time</title>
          <description>Loss of response was defined as a HAMD-17 total score &gt;9 and a CGI-Severity score &gt;2 at any one time during the double-blind maintenance phase of the study regardless of whether or not they subsequently regained response or not.</description>
          <population>Number of randomized patients with at least one non-missing post-baseline assessment during the double-blind maintenance therapy phase. Intent to Treat analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Frequencies were analyzed using Cochran-Mantel-Haenszel controlling for investigator.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score - Acute and Continuation Phases</title>
        <description>The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).</description>
        <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score - Acute and Continuation Phases</title>
          <description>The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).</description>
          <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.07" spread="3.55"/>
                    <measurement group_id="O2" value="6.64" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.37" spread="6.03"/>
                    <measurement group_id="O2" value="-0.61" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score - Maintenance Phase</title>
        <description>The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (absent, mild, moderate, severe, very severe) or a 3-point scale (absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).</description>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of randomized patients with a baseline and at least one non-missing post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score - Maintenance Phase</title>
          <description>The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (absent, mild, moderate, severe, very severe) or a 3-point scale (absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).</description>
          <population>Number of randomized patients with a baseline and at least one non-missing post-baseline measurement. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.53"/>
                    <measurement group_id="O2" value="4.36" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Clinical Global Impressions (CGI) Severity Scale - Acute and Continuation Phases</title>
        <description>Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).</description>
        <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Clinical Global Impressions (CGI) Severity Scale - Acute and Continuation Phases</title>
          <description>Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).</description>
          <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.49" spread="0.60"/>
                    <measurement group_id="O2" value="1.83" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" spread="1.08"/>
                    <measurement group_id="O2" value="-0.07" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.153</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Clinical Global Impressions (CGI) Severity Scale - Maintenance Phase</title>
        <description>Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients.</description>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of randomized patients with a baseline and at least one non-missing post-baseline assessment. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Clinical Global Impressions (CGI) Severity Scale - Maintenance Phase</title>
          <description>Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients.</description>
          <population>Number of randomized patients with a baseline and at least one non-missing post-baseline assessment. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.10"/>
                    <measurement group_id="O2" value="0.84" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values at Endpoint in Patient's Global Impressions of Improvement (PGI-I) - Acute and Continuation Phases</title>
        <description>A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
        <time_frame>Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Values at Endpoint in Patient's Global Impressions of Improvement (PGI-I) - Acute and Continuation Phases</title>
          <description>A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
          <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="488"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="0.86"/>
                    <measurement group_id="O2" value="1.76" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean value at endpoint is significant from 4.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean value at endpoint is significant from 4.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values at Endpoint in Patient's Global Impressions of Improvement (PGI-I) - Maintenance Phase</title>
        <description>A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
        <time_frame>Week 86 (Maintenance Phase)</time_frame>
        <population>Number of randomized patients with a baseline and at least one non-missing post-baseline assessment. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Values at Endpoint in Patient's Global Impressions of Improvement (PGI-I) - Maintenance Phase</title>
          <description>A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
          <population>Number of randomized patients with a baseline and at least one non-missing post-baseline assessment. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.11"/>
                    <measurement group_id="O2" value="2.34" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Hamilton Depression Rating Scale Subscales, Including the Core, Maier, Anxiety/Somatization, Retardation/Somatization, and Sleep Subscales, and the Depressed Mood Item - Acute and Continuation Phases</title>
        <description>Core and Maier subscales assess symptoms of depression (scores:0-20=Core; 0-24=Maier). Higher numbers indicate more severe symptoms. Anxiety/Somatization subscale assesses severity of anxiety (0-18). Retardation subscale assesses dysfunction in mood and work (0-14). Sleep subscale assesses insomnia (0-6). Depressed Mood Item (0-4).</description>
        <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Hamilton Depression Rating Scale Subscales, Including the Core, Maier, Anxiety/Somatization, Retardation/Somatization, and Sleep Subscales, and the Depressed Mood Item - Acute and Continuation Phases</title>
          <description>Core and Maier subscales assess symptoms of depression (scores:0-20=Core; 0-24=Maier). Higher numbers indicate more severe symptoms. Anxiety/Somatization subscale assesses severity of anxiety (0-18). Retardation subscale assesses dysfunction in mood and work (0-14). Sleep subscale assesses insomnia (0-6). Depressed Mood Item (0-4).</description>
          <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.71" spread="1.99"/>
                    <measurement group_id="O2" value="2.51" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.52" spread="2.63"/>
                    <measurement group_id="O2" value="-0.11" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.81" spread="1.78"/>
                    <measurement group_id="O2" value="2.00" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.97" spread="2.69"/>
                    <measurement group_id="O2" value="-0.29" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maier Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.44" spread="1.95"/>
                    <measurement group_id="O2" value="2.91" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maier Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.46" spread="3.29"/>
                    <measurement group_id="O2" value="-0.29" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retardation Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.76" spread="1.53"/>
                    <measurement group_id="O2" value="2.43" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retardation Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.61" spread="2.37"/>
                    <measurement group_id="O2" value="-0.48" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="1.59"/>
                    <measurement group_id="O2" value="1.11" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.37" spread="1.92"/>
                    <measurement group_id="O2" value="-0.07" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depressed Mood Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.78" spread="0.58"/>
                    <measurement group_id="O2" value="0.64" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depressed Mood Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="0.98"/>
                    <measurement group_id="O2" value="-0.05" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for Change from Baseline to Endpoint for all Subscales during Acute phase were &lt;0.001.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.334</p_value>
            <p_value_desc>P-value for Anxiety Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>P-value for Core Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.046</p_value>
            <p_value_desc>P-value for Maier Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assessses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Retardation Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assessses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.319</p_value>
            <p_value_desc>P-value for Sleep Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assessses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.275</p_value>
            <p_value_desc>P-value for Depressed Mood Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assessses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Hamilton Depression Rating Scale Subscales, Including the Core, Maier, Anxiety/Somatization, Retardation/Somatization, and Sleep Subscales, and the Depressed Mood Item - Maintenance Phase</title>
        <description>Core and Maier subscales assess symptoms of depression (scores:0-20=Core; 0-24=Maier). Higher numbers indicate more severe symptoms. Anxiety/Somatization subscale assesses severity of anxiety (0-18). Retardation subscale assesses dysfunction in mood and work (0-14). Sleep subscale assesses insomnia (0-6). Depressed Mood item (0-4).</description>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of randomized patients with a baseline and at least one non-missing post-baseline assessment. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Hamilton Depression Rating Scale Subscales, Including the Core, Maier, Anxiety/Somatization, Retardation/Somatization, and Sleep Subscales, and the Depressed Mood Item - Maintenance Phase</title>
          <description>Core and Maier subscales assess symptoms of depression (scores:0-20=Core; 0-24=Maier). Higher numbers indicate more severe symptoms. Anxiety/Somatization subscale assesses severity of anxiety (0-18). Retardation subscale assesses dysfunction in mood and work (0-14). Sleep subscale assesses insomnia (0-6). Depressed Mood item (0-4).</description>
          <population>Number of randomized patients with a baseline and at least one non-missing post-baseline assessment. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Endpoint in Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.20"/>
                    <measurement group_id="O2" value="1.54" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint in Core</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.22"/>
                    <measurement group_id="O2" value="1.74" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint in Maier</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.29"/>
                    <measurement group_id="O2" value="2.25" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint in Retardation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.20"/>
                    <measurement group_id="O2" value="1.49" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint in Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.12"/>
                    <measurement group_id="O2" value="0.71" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint in Depressed Mood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.09"/>
                    <measurement group_id="O2" value="0.67" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Pairwise comparison of Least Squares Means for Anxiety Subscale Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value for Pairwise comparison of Least Squares Means for Core Subscale Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value for Pairwise comparison of Least Squares Means for Maier Subscale Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value for Pairwise comparison of Least Squares Means for Retardation Subscale Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P-value for Pairwise comparison of Least Squares Means for Sleep Subscale Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value for Pairwise comparison of Least Squares Means for Depressed Mood Subscale Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Visual Analog Scales (VAS) for Pain - Acute and Continuation Phase</title>
        <description>VAS for pain consists of 6 questions that assess overall pain, headache, back pain, shoulder pain, pain interference with daily activities, and pain while awake. Participant rates pain on a 100 millimeter (mm) line between two anchors (0 = no pain and 100 = very severe pain).</description>
        <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Visual Analog Scales (VAS) for Pain - Acute and Continuation Phase</title>
          <description>VAS for pain consists of 6 questions that assess overall pain, headache, back pain, shoulder pain, pain interference with daily activities, and pain while awake. Participant rates pain on a 100 millimeter (mm) line between two anchors (0 = no pain and 100 = very severe pain).</description>
          <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
                <count group_id="O2" value="410"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Pain Baseline (N=450, N=410)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.36" spread="26.16"/>
                    <measurement group_id="O2" value="17.29" spread="20.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Pain Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.34" spread="26.95"/>
                    <measurement group_id="O2" value="1.16" spread="21.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Baseline (N=450, N=410)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.74" spread="28.08"/>
                    <measurement group_id="O2" value="14.80" spread="20.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.83" spread="28.04"/>
                    <measurement group_id="O2" value="0.04" spread="21.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back Pain Baseline (N=450, N=410)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.79" spread="27.80"/>
                    <measurement group_id="O2" value="15.61" spread="22.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back Pain Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.64" spread="25.66"/>
                    <measurement group_id="O2" value="-0.00" spread="20.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shoulder Pain Baseline (N=446, N=410)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.06" spread="27.23"/>
                    <measurement group_id="O2" value="13.49" spread="21.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shoulder Pain Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.47" spread="24.25"/>
                    <measurement group_id="O2" value="-0.39" spread="20.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interference-DailyActivities Baseline(N=445,N=410)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.28" spread="28.31"/>
                    <measurement group_id="O2" value="15.59" spread="21.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intereference Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.79" spread="29.77"/>
                    <measurement group_id="O2" value="1.00" spread="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain While Awake Baseline (N=446, N=410)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.18" spread="29.29"/>
                    <measurement group_id="O2" value="19.22" spread="25.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain While Awake Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.66" spread="31.22"/>
                    <measurement group_id="O2" value="0.06" spread="25.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for all Change from Baseline to Endpoint measures in the Acute Phase were &lt;0.001.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.273</p_value>
            <p_value_desc>P-value for Overall Pain Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.968</p_value>
            <p_value_desc>P-value for Headache Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.998</p_value>
            <p_value_desc>P-value for Back Pain Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.703</p_value>
            <p_value_desc>P-value for Shoulder Pain Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.346</p_value>
            <p_value_desc>P-value for Interference with Daily Activities Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.963</p_value>
            <p_value_desc>P-value for Pain While Awake Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Visual Analog Scales (VAS) for Pain - Maintenance Phase</title>
        <description>VAS for pain consists of 6 questions that assess overall pain, headache, back pain, shoulder pain, pain interference with daily activities, and pain while awake. Participant rates pain on a 100 millimeter (mm) line between two anchors (0 = no pain and 100 = very severe pain).</description>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of randomized patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Visual Analog Scales (VAS) for Pain - Maintenance Phase</title>
          <description>VAS for pain consists of 6 questions that assess overall pain, headache, back pain, shoulder pain, pain interference with daily activities, and pain while awake. Participant rates pain on a 100 millimeter (mm) line between two anchors (0 = no pain and 100 = very severe pain).</description>
          <population>Number of randomized patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Endpoint in Overall Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" spread="1.78"/>
                    <measurement group_id="O2" value="4.57" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint in Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" spread="1.72"/>
                    <measurement group_id="O2" value="2.80" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint in Back Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="1.65"/>
                    <measurement group_id="O2" value="3.40" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint in Shoulder Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="1.55"/>
                    <measurement group_id="O2" value="3.02" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change: Interference with Daily Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="1.74"/>
                    <measurement group_id="O2" value="2.81" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline in Pain While Awake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="2.10"/>
                    <measurement group_id="O2" value="4.69" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.792</p_value>
            <p_value_desc>P-value for pairwise comparison of Least Squares Means for Overall Pain Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.407</p_value>
            <p_value_desc>P-value for pairwise comparison of Least Squares Means for Headache Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.475</p_value>
            <p_value_desc>P-value for pairwise comparison of Least Squares Means for Back Pain Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.241</p_value>
            <p_value_desc>P-value for pairwise comparison of Least Squares Means for Shoulder Pain Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.885</p_value>
            <p_value_desc>P-value for pairwise comparison of Least Squares Means for Interference with Daily Activities Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.717</p_value>
            <p_value_desc>P-value for pairwise comparison of Least Squares Means for Pain While Awake Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Symptom Questionnaire-Somatic Subscale (SQ-SS) - Acute and Continuation Phases</title>
        <description>The Somatic subscale consists of 23 items to be completed by the patient that focus on somatic symptoms. Question answers are either yes/no or true/false. Negative response is scored at 1; positive response is scored as 0. Total Somatic subscale scores range from 0-23, where higher scores indicate greater symptom severity.</description>
        <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Symptom Questionnaire-Somatic Subscale (SQ-SS) - Acute and Continuation Phases</title>
          <description>The Somatic subscale consists of 23 items to be completed by the patient that focus on somatic symptoms. Question answers are either yes/no or true/false. Negative response is scored at 1; positive response is scored as 0. Total Somatic subscale scores range from 0-23, where higher scores indicate greater symptom severity.</description>
          <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.64" spread="5.09"/>
                    <measurement group_id="O2" value="6.88" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.37" spread="5.42"/>
                    <measurement group_id="O2" value="-0.35" spread="4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.157</p_value>
            <p_value_desc>P-value for Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Symptom Questionnaire-Somatic Subscale (SQ-SS) - Maintenance Phase</title>
        <description>The Somatic subscale consists of 23 items to be completed by the patient that focus on somatic symptoms. Question answers are either yes/no or true/false. Negative response is scored at 1; positive response is scored as 0. Total Somatic subscale scores range from 0-23, where higher scores indicate greater symptom severity.</description>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of randomized patients with non-missing baseline and at least one non-missing post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Symptom Questionnaire-Somatic Subscale (SQ-SS) - Maintenance Phase</title>
          <description>The Somatic subscale consists of 23 items to be completed by the patient that focus on somatic symptoms. Question answers are either yes/no or true/false. Negative response is scored at 1; positive response is scored as 0. Total Somatic subscale scores range from 0-23, where higher scores indicate greater symptom severity.</description>
          <population>Number of randomized patients with non-missing baseline and at least one non-missing post-baseline measurement. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.39"/>
                    <measurement group_id="O2" value="0.81" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.979</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Acute and Continuation Phases</title>
        <description>The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total (Global) scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life. Individual Item scores range from 0 to 10.</description>
        <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Acute and Continuation Phases</title>
          <description>The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total (Global) scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life. Individual Item scores range from 0 to 10.</description>
          <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="452"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global Score Baseline (N=449,N=378)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.30" spread="6.58"/>
                    <measurement group_id="O2" value="10.72" spread="7.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Score Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.88" spread="8.06"/>
                    <measurement group_id="O2" value="-2.01" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work/School Item Baseline (N=452,N=378)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.52" spread="2.52"/>
                    <measurement group_id="O2" value="3.64" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work/School Item Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.61" spread="2.87"/>
                    <measurement group_id="O2" value="-0.71" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Life Item Baseline (N=452,N=378)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" spread="2.42"/>
                    <measurement group_id="O2" value="3.50" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Life Item Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.69" spread="2.90"/>
                    <measurement group_id="O2" value="-0.64" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family Life Item Baseline (N=452,N=378)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" spread="2.44"/>
                    <measurement group_id="O2" value="3.54" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family Life Item Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.59" spread="3.07"/>
                    <measurement group_id="O2" value="-0.63" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline to Endpoint in all SDS items in Acute Phase were &lt;0.001.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline to Endpoint in all SDS items in the Continuation Phase were &lt;0.001.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Maintenance Phase</title>
        <description>The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total (Global) scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life. Individual Item scores range from 0 to 10.</description>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of randomized patients with non-missing baseline and at least one non-missing post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Maintenance Phase</title>
          <description>The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total (Global) scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life. Individual Item scores range from 0 to 10.</description>
          <population>Number of randomized patients with non-missing baseline and at least one non-missing post-baseline measurement. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Endpoint in Global Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.71"/>
                    <measurement group_id="O2" value="2.06" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint in Work/School</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.26"/>
                    <measurement group_id="O2" value="0.83" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint in Social Life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.25"/>
                    <measurement group_id="O2" value="0.56" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint in Family Life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.25"/>
                    <measurement group_id="O2" value="0.67" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>P-value for pairwise comparison of Least Squares Means for Change from Baseline to Endpoint in Global Score</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <p_value_desc>P-value for pairwise comparison of Least Squares Means for Change from Baseline to Endpoint in Work/School.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.110</p_value>
            <p_value_desc>P-value for pairwise comparison of Least Squares Means for Change from Baseline to Endpoint in Social Life.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>P-value for pairwise comparison of Least Squares Means for Change from Baseline to Endpoint in Family Life/Home Responsibilities.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in 36-item Short-Form Health Survey (SF-36) - Acute and Continuation Phase</title>
        <description>Assesses general quality of life. 36 questions covering 8 health domains. Each subscale is scored by summing the individual items and transforming scores into a 0-100 scale, with higher scores indicating better health status or functioning.</description>
        <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in 36-item Short-Form Health Survey (SF-36) - Acute and Continuation Phase</title>
          <description>Assesses general quality of life. 36 questions covering 8 health domains. Each subscale is scored by summing the individual items and transforming scores into a 0-100 scale, with higher scores indicating better health status or functioning.</description>
          <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="460"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component Summary Baseline (N=455,N=377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.55" spread="9.46"/>
                    <measurement group_id="O2" value="48.05" spread="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Summary Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="8.66"/>
                    <measurement group_id="O2" value="0.03" spread="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Summary Baseline (N=455,N=377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.93" spread="8.76"/>
                    <measurement group_id="O2" value="39.83" spread="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Summary Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.67" spread="11.77"/>
                    <measurement group_id="O2" value="3.98" spread="12.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning Baseline (N=457,N=377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.59" spread="4.75"/>
                    <measurement group_id="O2" value="26.28" spread="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="4.40"/>
                    <measurement group_id="O2" value="0.28" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain Baseline (N=460,N=377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.83" spread="2.45"/>
                    <measurement group_id="O2" value="8.61" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="2.50"/>
                    <measurement group_id="O2" value="0.07" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitations:Physical Baseline (N=457,N=377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" spread="1.47"/>
                    <measurement group_id="O2" value="6.48" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitations:Physical Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.78"/>
                    <measurement group_id="O2" value="0.20" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitations:Emotional Baseline (N=456,N=377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" spread="0.80"/>
                    <measurement group_id="O2" value="4.65" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitations:Emotional Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="1.31"/>
                    <measurement group_id="O2" value="0.34" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health Perceptions Baseline(N=456,N=377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.66" spread="3.62"/>
                    <measurement group_id="O2" value="17.03" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health Perceptions Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" spread="3.74"/>
                    <measurement group_id="O2" value="0.58" spread="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health Baseline (N=456,N=377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.62" spread="4.13"/>
                    <measurement group_id="O2" value="19.60" spread="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" spread="5.31"/>
                    <measurement group_id="O2" value="1.30" spread="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Function Baseline (N=460,N=377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" spread="1.74"/>
                    <measurement group_id="O2" value="7.05" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Function Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="2.04"/>
                    <measurement group_id="O2" value="0.65" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality Baseline (N=457,N=377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.85" spread="3.26"/>
                    <measurement group_id="O2" value="13.84" spread="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.51" spread="4.22"/>
                    <measurement group_id="O2" value="0.84" spread="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rate Current Health Baseline (N=460,N=377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="0.85"/>
                    <measurement group_id="O2" value="3.03" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rate Current Health Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.95"/>
                    <measurement group_id="O2" value="-0.01" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Health Compared to Year Ago Baseline (N=460,N=377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="0.99"/>
                    <measurement group_id="O2" value="2.37" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Health Compared to Year Ago Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="1.28"/>
                    <measurement group_id="O2" value="-0.34" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for Change from Baseline to Endpoint in all SF-36 subscales in the Acute Phase were &lt;0.001</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.947</p_value>
            <p_value_desc>P-value for Physical Component Summary Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Mental Component Summary Change to Endpoint</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.118</p_value>
            <p_value_desc>P-value for Physical Functioning Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.550</p_value>
            <p_value_desc>P-value for Bodily Pain Change from Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>P-value for Role Limitations Due to Physical Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Role Limitations Due to Emotional Problems Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value for General Health Perceptions Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Mental Health Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Social Function Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Vitality Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.815</p_value>
            <p_value_desc>P-value for Rate Current Health Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Health Compared to a Year Ago Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in 36-item Short-Form Health Survey (SF-36) - Maintenance Phase</title>
        <description>Assesses general quality of life. 36 questions covering 8 health domains. Each subscale is scored by summing the individual items and transforming scores into a 0-100 scale, with higher scores indicating better health status or functioning.</description>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of randomized patients with non-missing baseline and at least one non-missing post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in 36-item Short-Form Health Survey (SF-36) - Maintenance Phase</title>
          <description>Assesses general quality of life. 36 questions covering 8 health domains. Each subscale is scored by summing the individual items and transforming scores into a 0-100 scale, with higher scores indicating better health status or functioning.</description>
          <population>Number of randomized patients with non-missing baseline and at least one non-missing post-baseline measurement. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline-Physical Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.70"/>
                    <measurement group_id="O2" value="0.33" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline-Mental Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.11" spread="1.11"/>
                    <measurement group_id="O2" value="-5.74" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline-Physical Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.28"/>
                    <measurement group_id="O2" value="-0.07" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline-Bodily Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.22"/>
                    <measurement group_id="O2" value="-0.19" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline-Role Limitations: Physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.14"/>
                    <measurement group_id="O2" value="-0.41" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline-Role Limitations: Emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.11"/>
                    <measurement group_id="O2" value="-0.46" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline-General Health Perceptions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.33"/>
                    <measurement group_id="O2" value="-0.61" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline-Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.49"/>
                    <measurement group_id="O2" value="-2.60" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline-Social Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.18"/>
                    <measurement group_id="O2" value="-0.50" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline-Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.38"/>
                    <measurement group_id="O2" value="-1.38" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline-Rate Current Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.08"/>
                    <measurement group_id="O2" value="0.08" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline-Health Compared to Year Ago</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.09"/>
                    <measurement group_id="O2" value="0.34" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.415</p_value>
            <p_value_desc>P-value is pairwise comparison of Least Squares Means for Change from Baseline-Physical Component Summary.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value is pairwise comparison of Least Squares Means for Change from Baseline-Mental Component Summary.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.731</p_value>
            <p_value_desc>P-value is pairwise comparison of Least Squares Means for Change from Baseline-Physical Functioning.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.438</p_value>
            <p_value_desc>P-value is pairwise comparison of Least Squares Means for Change from Baseline-Bodily Pain.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>P-value is pairwise comparison of Least Squares Means for Change from Baseline-Role Limitations Due to Physical.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value is pairwise comparison of Least Squares Means for Change from Baseline-Role Limitations Due to Emotional problems.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.391</p_value>
            <p_value_desc>P-value is pairwise comparison of Least Squares Means for Change from Baseline-General Health Perceptions.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P-value is pairwise comparison of Least Squares Means for Change from Baseline-Mental Health.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.142</p_value>
            <p_value_desc>P-value is pairwise comparison of Least Squares Means for Change from Baseline-Social Functioning.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.240</p_value>
            <p_value_desc>P-value is pairwise comparison of Least Squares Means for Change from Baseline-Vitality.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.615</p_value>
            <p_value_desc>P-value is pairwise comparison of Least Squares Means for Change from Baseline-Rate General Health.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.218</p_value>
            <p_value_desc>P-value is pairwise comparison of Least Squares Means for Change from Baseline-Health Compared to a Year Ago.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resource Utilization and Hospitalization Module - Visits to Health Care Providers - Acute and Continuation Phases</title>
        <description>Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.</description>
        <time_frame>Week 0 through Week10 (Acute) through Week 34 (Continuation)</time_frame>
        <population>Number of enrolled patients in Acute Phase and number who entered Continuation Phase who indicated they had visits to specified health care provider. Intent to Treat analysis. Note: &quot;Other Mental Health Care Worker&quot; wasn't included in table (1 patient in Acute). &quot;Other Health Care Worker&quot; wasnt included in table (2 patients in Continuation).</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Resource Utilization and Hospitalization Module - Visits to Health Care Providers - Acute and Continuation Phases</title>
          <description>Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.</description>
          <population>Number of enrolled patients in Acute Phase and number who entered Continuation Phase who indicated they had visits to specified health care provider. Intent to Treat analysis. Note: &quot;Other Mental Health Care Worker&quot; wasn't included in table (1 patient in Acute). &quot;Other Health Care Worker&quot; wasnt included in table (2 patients in Continuation).</population>
          <units>visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="514"/>
                <count group_id="O2" value="413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Health Care Provider Visits (N=94,N=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.03"/>
                    <measurement group_id="O2" value="-0.00" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatrist Visits (N=91,N=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.03"/>
                    <measurement group_id="O2" value="-0.03" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychologist/Therapist Visits (N=19,N=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.04"/>
                    <measurement group_id="O2" value="-0.00" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Specialist Physician Visits (N=42,N=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.02"/>
                    <measurement group_id="O2" value="0.01" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (Specified by Patient) Visits (N=3,N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.07"/>
                    <measurement group_id="O2" value="-0.07" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.838</p_value>
            <p_value_desc>P-value for change in number of Primary Health Care Provider Visits in Acute Phase</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for change in number of Psychiatrist visits in Acute Phase</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.236</p_value>
            <p_value_desc>P-value for change in number of Psychologist/Therapist visits in Acute Phase</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.145</p_value>
            <p_value_desc>P-value for change in number of Other Specialist Physician visits in Acute Phase</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.423</p_value>
            <p_value_desc>P-value for change in number of Other (Specified by Patient) visits in Acute Phase</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.325</p_value>
            <p_value_desc>P-value for change in number of Primary Health Care Provider visits in Continuation Phase</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for change in number of Psychiatrist visits in Continuation Phase</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.915</p_value>
            <p_value_desc>P-value for change in number of Psychologist/Therapist visits in Continuation Phase</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.223</p_value>
            <p_value_desc>P-value for change in number of Other Specialist Physician visits in Continuation Phase</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.362</p_value>
            <p_value_desc>P-value for change in number of Other (Specified by Patient) visits in Continuation Phase</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resource Utilization and Hospitalization Module - Visits to Health Care Providers - Maintenance Phase</title>
        <description>Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.</description>
        <time_frame>Week 34 through Week 86 (Maintenance Phase)</time_frame>
        <population>Number of randomized patients who indicated they had visits to specified health care provider. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Resource Utilization and Hospitalization Module - Visits to Health Care Providers - Maintenance Phase</title>
          <description>Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.</description>
          <population>Number of randomized patients who indicated they had visits to specified health care provider. Intent to Treat analysis.</population>
          <units>visits</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Health Care Provider Visits (N=47,N=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.00"/>
                    <measurement group_id="O2" value="-0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatrist Visits (N=33,N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.00"/>
                    <measurement group_id="O2" value="-0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychologist/Therapist Visits (N=8,N=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.01"/>
                    <measurement group_id="O2" value="-0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Specialist Physician Visits (N=25,N=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.01"/>
                    <measurement group_id="O2" value="-0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (Specified by Patient) Visits (N=5,N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.02"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.462</p_value>
            <p_value_desc>P-value for pairwise comparison of means for change from baseline to endpoint in Primary Health Care Provider visits.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.668</p_value>
            <p_value_desc>P-value for pairwise comparison of means for change from baseline to endpoint in Psychiatrist visits.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.746</p_value>
            <p_value_desc>P-value for pairwise comparison of means for change from baseline to endpoint in Psychologist/Therapist visits.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.511</p_value>
            <p_value_desc>P-value for pairwise comparison of means for change from baseline to endpoint in Other Specialist Physician visits.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.271</p_value>
            <p_value_desc>P-value for pairwise comparison of means for change from baseline to endpoint in Other (Specified by Patient) Provider visits.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Average Number of Hours Worked in a Week - Acute and Continuation Phases</title>
        <description>Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.</description>
        <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of enrolled patients in the Acute Phase who work for pay. Number of patients who entered the Continuation Phase who work for pay. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Average Number of Hours Worked in a Week - Acute and Continuation Phases</title>
          <description>Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.</description>
          <population>Number of enrolled patients in the Acute Phase who work for pay. Number of patients who entered the Continuation Phase who work for pay. Intent to Treat analysis.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average Number of Hours Worked In a Week Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.10"/>
                    <measurement group_id="O2" value="0.36" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Average Number of Hours Worked In a Week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.06"/>
                    <measurement group_id="O2" value="0.01" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.506</p_value>
            <p_value_desc>P-value for Change in Average Number of Hours Worked In a Week in Acute Phase</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.057</p_value>
            <p_value_desc>P-value for Change in Average Number of Hours Worked In a Week in Continuation Phase</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Average Number of Hours Worked in a Week - Maintenance Phase</title>
        <description>Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.</description>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of randomized patients who work for pay. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Average Number of Hours Worked in a Week - Maintenance Phase</title>
          <description>Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.</description>
          <population>Number of randomized patients who work for pay. Intent to Treat analysis.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.01"/>
                    <measurement group_id="O2" value="-0.00" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.826</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Number of Missed Paid Work Hours - Acute and Continuation Phase</title>
        <description>Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.</description>
        <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of enrolled patients in the Acute Phase who work for pay and missed work due to illness. Number of patients who entered the Continuation Phase who work for pay and missed work due to illness. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute</title>
            <description>duloxetine 60-120 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Number of Missed Paid Work Hours - Acute and Continuation Phase</title>
          <description>Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.</description>
          <population>Number of enrolled patients in the Acute Phase who work for pay and missed work due to illness. Number of patients who entered the Continuation Phase who work for pay and missed work due to illness. Intent to Treat analysis.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Missed Paid Work Hours Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="2.07"/>
                    <measurement group_id="O2" value="2.67" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Number of Missed Paid Work Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="2.25"/>
                    <measurement group_id="O2" value="-0.52" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.105</p_value>
            <p_value_desc>P-value for Change in Number of Missed Paid Work Hours in Acute Phase</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.174</p_value>
            <p_value_desc>P-value for Change in Number of Missed Paid Work Hours in Continuation Phase</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Number of Missed Paid Work Hours - Maintenance Phase</title>
        <description>Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.</description>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of randomized patients who work for pay and missed work due to illness. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Number of Missed Paid Work Hours - Maintenance Phase</title>
          <description>Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.</description>
          <population>Number of randomized patients who work for pay and missed work due to illness. Intent to Treat analysis.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.28"/>
                    <measurement group_id="O2" value="-0.75" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Males)</title>
        <description>A 5-item patient-rated scale measuring 5 domains: sexual drive, arousal (subjective excitement), lubrication/erection (physiological excitement), ability to reach orgasm, orgasm satisfaction. Higher score means worse dysfunction. Total score range is 5-30.</description>
        <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of male enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of male patients who entered Continuation Phase with a baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Males)</title>
          <description>A 5-item patient-rated scale measuring 5 domains: sexual drive, arousal (subjective excitement), lubrication/erection (physiological excitement), ability to reach orgasm, orgasm satisfaction. Higher score means worse dysfunction. Total score range is 5-30.</description>
          <population>Number of male enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of male patients who entered Continuation Phase with a baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sum Items 1 to 5 Baseline (N=117,N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.57" spread="4.88"/>
                    <measurement group_id="O2" value="17.26" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sum Items 1 to 5 Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="5.08"/>
                    <measurement group_id="O2" value="-0.67" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sum Items 1&amp;2 Baseline (N=135, N=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.47" spread="2.19"/>
                    <measurement group_id="O2" value="7.16" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sum Items 1&amp;2 Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="2.32"/>
                    <measurement group_id="O2" value="-0.39" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 1-Sex Drive Baseline (N=136,N=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" spread="1.20"/>
                    <measurement group_id="O2" value="3.68" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 1-Sex Drive Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="1.30"/>
                    <measurement group_id="O2" value="-0.21" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 2-Arousal Baseline (N=135, N=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="1.11"/>
                    <measurement group_id="O2" value="3.48" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 2-Arousal Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="1.17"/>
                    <measurement group_id="O2" value="-0.18" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 3-Lubrication/Erection Baseline (N=124,N=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="1.13"/>
                    <measurement group_id="O2" value="3.27" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 3-Lubrication Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="1.15"/>
                    <measurement group_id="O2" value="-0.04" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 4-Orgasm Baseline (N=120,N=98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="1.10"/>
                    <measurement group_id="O2" value="3.60" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 4-Orgasm Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="1.30"/>
                    <measurement group_id="O2" value="-0.15" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 5-Satisfaction Baseline (N=118,N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="1.17"/>
                    <measurement group_id="O2" value="3.32" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 5-Satisfaction Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="1.29"/>
                    <measurement group_id="O2" value="-0.15" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.785</p_value>
            <p_value_desc>P-value for Sum Items 1 to 5 Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.354</p_value>
            <p_value_desc>P-value for Sum Items 1&amp;2 Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.170</p_value>
            <p_value_desc>P-value for Item 1-Sex Drive Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.825</p_value>
            <p_value_desc>P-value for Item 2-Arousal Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.877</p_value>
            <p_value_desc>P-value for Item 3-Vaginal Lubrication/Penile Erection Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>P-value for Item 4-Orgasm Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.670</p_value>
            <p_value_desc>P-value for Item 5-Satisfaction Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.100</p_value>
            <p_value_desc>P-value for Sum Items 1 to 5 Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>P-value for Sum Items 1&amp;2 Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <p_value_desc>P-value for Item 1-Sex Drive Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>P-value for Item 2-Arousal Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.668</p_value>
            <p_value_desc>P-value for Item 3-Vaginal Lubrication/Penile Erection Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.136</p_value>
            <p_value_desc>P-value for Item 4-Orgasm Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.152</p_value>
            <p_value_desc>P-value for Item 5-Satisfaction Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Females)</title>
        <description>A 5-item patient-rated scale measuring 5 domains: sexual drive, arousal (subjective excitement), lubrication/erection (physiological excitement), ability to reach orgasm, orgasm satisfaction. Higher score means worse dysfunction. Total score range is 5-30.</description>
        <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of female enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of female patients who entered Continuation Phase with a baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Females)</title>
          <description>A 5-item patient-rated scale measuring 5 domains: sexual drive, arousal (subjective excitement), lubrication/erection (physiological excitement), ability to reach orgasm, orgasm satisfaction. Higher score means worse dysfunction. Total score range is 5-30.</description>
          <population>Number of female enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of female patients who entered Continuation Phase with a baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sum Items 1 to 5 Baseline (N=220,N=197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.41" spread="5.17"/>
                    <measurement group_id="O2" value="19.31" spread="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sum Items 1 to 5 Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="3.91"/>
                    <measurement group_id="O2" value="-0.99" spread="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sum Items 1&amp;2 Baseline (N=285,N=239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.31" spread="2.08"/>
                    <measurement group_id="O2" value="8.42" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sum Items 1&amp;2 Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="1.91"/>
                    <measurement group_id="O2" value="-0.56" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 1-Sex Drive Baseline (N=286,N=239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="1.12"/>
                    <measurement group_id="O2" value="4.34" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 1-Sex Drive Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="1.05"/>
                    <measurement group_id="O2" value="-0.31" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 2-Arousal Baseline (N=286,N=239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" spread="1.13"/>
                    <measurement group_id="O2" value="4.08" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 2-Arousal Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="1.07"/>
                    <measurement group_id="O2" value="-0.25" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 3-Lubrication/Erection Baseline (N=224,N=198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" spread="1.26"/>
                    <measurement group_id="O2" value="3.57" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 3-Lubrication/Erection Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.98"/>
                    <measurement group_id="O2" value="-0.10" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 4-Orgasm Baseline (N=224,N=198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="1.19"/>
                    <measurement group_id="O2" value="4.06" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item4-Orgasm Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="1.02"/>
                    <measurement group_id="O2" value="-0.28" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 5-Satisfaction Baseline (N=226,N=198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread="1.39"/>
                    <measurement group_id="O2" value="3.58" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 5-Satisfaction Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="1.18"/>
                    <measurement group_id="O2" value="-0.10" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Sum Items 1 to 5 Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Sum Items 1&amp;2 Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Item 1-Sex Drive Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Item 2-Arousal Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>P-value for Item 3-Vaginal Lubrication/Penile Erection Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <p_value_desc>P-value for Item 4-Orgasm Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <p_value_desc>P-value for Item 5-Satisfaction Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value for Sum Items 1 to 5 Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Sum Items 1&amp;2 Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Item 1-Sex Drive Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Item 2-Arousal Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.186</p_value>
            <p_value_desc>P-value for Item 3-Vaginal Lubrication/Penile Erection Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Item 4-Orgasm Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.308</p_value>
            <p_value_desc>P-value for Item 5-Satisfaction Change to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Maintenance Phase (Males)</title>
        <description>A 5-item patient-rated scale measuring 5 domains: sexual drive, arousal (subjective excitement), lubrication/erection (physiological excitement), ability to reach orgasm, orgasm satisfaction. Higher score means worse dysfunction. Total score range is 5-30.</description>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>N=Number of male randomized patients with non-missing baseline and at least one non-missing post-baseline measurement. Male patients who have been sexually active in the previous month respond to Items 3-5. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Maintenance Phase (Males)</title>
          <description>A 5-item patient-rated scale measuring 5 domains: sexual drive, arousal (subjective excitement), lubrication/erection (physiological excitement), ability to reach orgasm, orgasm satisfaction. Higher score means worse dysfunction. Total score range is 5-30.</description>
          <population>N=Number of male randomized patients with non-missing baseline and at least one non-missing post-baseline measurement. Male patients who have been sexually active in the previous month respond to Items 3-5. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline: Sum Items 1 to 5 (N=35,N=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="0.47"/>
                    <measurement group_id="O2" value="-0.77" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline: Sum Items 1&amp;2 (N=39,N=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.22"/>
                    <measurement group_id="O2" value="0.03" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 1-Sex Drive (N=39,N=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.13"/>
                    <measurement group_id="O2" value="-0.02" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 2-Arousal (N=39,N=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.12"/>
                    <measurement group_id="O2" value="0.07" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 3-Lubrication/Erection (N=38,N=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.14"/>
                    <measurement group_id="O2" value="-0.10" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 4-Orgasm (N=36,N=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.14"/>
                    <measurement group_id="O2" value="-0.43" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 5-Satisfaction (N=35,N=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.11"/>
                    <measurement group_id="O2" value="-0.04" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.773</p_value>
            <p_value_desc>P-value for pairwise comparison Least Squares Mean change from baseline for the Sum of Items 1 to 5.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.405</p_value>
            <p_value_desc>P-value for pairwise comparison Least Squares Mean change from baseline for the Sum of Items 1 and 2.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.443</p_value>
            <p_value_desc>P-value for pairwise comparison Least Squares Mean change from baseline for Item 1-Sex Drive.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.384</p_value>
            <p_value_desc>P-value for pairwise comparison Least Squares Mean change from baseline for Item 2-Arousal.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.268</p_value>
            <p_value_desc>P-value for pairwise comparison Least Squares Mean change from baseline for Item 3-Vaginal Lubrication/Penile Erection.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.093</p_value>
            <p_value_desc>P-value for pairwise comparison Least Squares Mean change from baseline for Item 4-Orgasm.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.566</p_value>
            <p_value_desc>P-value for pairwise comparison Least Squares Mean change from baseline for Item 5-Satisfaction.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Maintenance Phase (Females)</title>
        <description>A 5-item patient-rated scale measuring 5 domains: sexual drive, arousal (subjective excitement), lubrication/erection (physiological excitement), ability to reach orgasm, orgasm satisfaction. Higher score means worse dysfunction. Total score range is 5-30.</description>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>N=Number of female randomized patients with non-missing baseline and at least one non-missing post-baseline measurement. Female patients who have been sexually active in the previous month respond to Items 3-5. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Maintenance Phase (Females)</title>
          <description>A 5-item patient-rated scale measuring 5 domains: sexual drive, arousal (subjective excitement), lubrication/erection (physiological excitement), ability to reach orgasm, orgasm satisfaction. Higher score means worse dysfunction. Total score range is 5-30.</description>
          <population>N=Number of female randomized patients with non-missing baseline and at least one non-missing post-baseline measurement. Female patients who have been sexually active in the previous month respond to Items 3-5. Intent to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline:Sum Items 1 to 5 (N=63,N=66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="4.14"/>
                    <measurement group_id="O2" value="-0.47" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline:Sum Items 1&amp;2 (N=77,N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="1.90"/>
                    <measurement group_id="O2" value="0.34" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 1 - Sex Drive (N=77,N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="1.11"/>
                    <measurement group_id="O2" value="0.18" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 2 - Arousal (N=77,N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.95"/>
                    <measurement group_id="O2" value="0.16" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 3 - Lubrication/Erection (N=63,N=67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.92"/>
                    <measurement group_id="O2" value="-0.15" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 4 - Orgasm (N=63,N=67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.96"/>
                    <measurement group_id="O2" value="-0.15" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 5 - Satisfaction (N=63,N=67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="1.25"/>
                    <measurement group_id="O2" value="-0.40" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.979</p_value>
            <p_value_desc>P-value for pairwise comparison Least Squares Mean change from baseline for the Sum of Items 1 to 5.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.132</p_value>
            <p_value_desc>P-value for pairwise comparison Least Squares Mean change from baseline for the Sum of Items 1 and 2.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.180</p_value>
            <p_value_desc>P-value for pairwise comparison Least Squares Mean change from baseline for Item 1-Sex Drive.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.163</p_value>
            <p_value_desc>P-value for pairwise comparison Least Squares Mean change from baseline for Item 2-Arousal.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.844</p_value>
            <p_value_desc>P-value for pairwise comparison Least Squares Mean change from baseline for Item 3-Vaginal Lubrication/Penile Erection.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.609</p_value>
            <p_value_desc>P-value for pairwise comparison Least Squares Mean change from baseline for Item 4-Orgasm.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.071</p_value>
            <p_value_desc>P-value for pairwise comparison Least Squares Mean change from baseline for Item 5-Satisfaction.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Change From Baseline to Endpoint in Weight - Acute and Continuation Phases</title>
        <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Change From Baseline to Endpoint in Weight - Acute and Continuation Phases</title>
          <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.74" spread="16.25"/>
                    <measurement group_id="O2" value="74.22" spread="15.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="2.12"/>
                    <measurement group_id="O2" value="0.88" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Weight Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Weight Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Change From Baseline to Endpoint in Weight - Maintenance Phase</title>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of randomized patients with baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Change From Baseline to Endpoint in Weight - Maintenance Phase</title>
          <population>Number of randomized patients with baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.36"/>
                    <measurement group_id="O2" value="0.39" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.314</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Change From Baseline to Endpoint in Pulse - Acute and Continuation Phases</title>
        <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Change From Baseline to Endpoint in Pulse - Acute and Continuation Phases</title>
          <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulse Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.76" spread="9.26"/>
                    <measurement group_id="O2" value="72.79" spread="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="9.18"/>
                    <measurement group_id="O2" value="1.75" spread="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Pulse Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Pulse Change from Baseline to Endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Change From Baseline to Endpoint in Pulse - Maintenance Phase</title>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of randomized patients with baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Change From Baseline to Endpoint in Pulse - Maintenance Phase</title>
          <population>Number of randomized patients with baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="0.76"/>
                    <measurement group_id="O2" value="-1.72" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.891</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Change From Baseline to Endpoint in Blood Pressure - Acute and Continuation Phases</title>
        <time_frame>Week 0 and Week 10 (Acute) and Week 34 (Continuation)</time_frame>
        <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Change From Baseline to Endpoint in Blood Pressure - Acute and Continuation Phases</title>
          <population>Number of enrolled patients in the Acute Phase with a baseline and at least one non-missing post-baseline measurement. Number of patients who entered Continuation phase with baseline and have at least 1 post-baseline measurement. Intent to Treat analysis.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.03" spread="14.65"/>
                    <measurement group_id="O2" value="124.72" spread="13.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="12.62"/>
                    <measurement group_id="O2" value="0.77" spread="12.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.52" spread="9.54"/>
                    <measurement group_id="O2" value="78.28" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="8.68"/>
                    <measurement group_id="O2" value="-0.57" spread="9.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.659</p_value>
            <p_value_desc>P-value for systolic blood pressure change to endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <p_value_desc>P-value for diastolic blood pressure change to endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.224</p_value>
            <p_value_desc>P-value for systolic blood pressure change to endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.210</p_value>
            <p_value_desc>P-value for diastolic blood pressure change to endpoint.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Change From Baseline to Endpoint in Blood Pressure - Maintenance Phase</title>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of randomized patients with baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Change From Baseline to Endpoint in Blood Pressure - Maintenance Phase</title>
          <population>Number of randomized patients with baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline: Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="13.44"/>
                    <measurement group_id="O2" value="-1.11" spread="11.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline: Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="9.72"/>
                    <measurement group_id="O2" value="-0.11" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.134</p_value>
            <p_value_desc>P-value for Change from Baseline: systolic blood pressure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.816</p_value>
            <p_value_desc>P-value for Change from Baseline: diastolic blood pressure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Albumin - Acute Phase</title>
        <time_frame>Week 0 and Week 10</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Albumin - Acute Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>grams per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.05" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Acute Phase</title>
        <time_frame>Week 0 and Week 10</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Acute Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>millimoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.007</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Chloride - Acute Phase</title>
        <time_frame>Week 0 and Week 10</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Chloride - Acute Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>millimoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.73" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.035</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Eosinophils - Acute Phase</title>
        <time_frame>Week 0 and Week 10</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Eosinophils - Acute Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>Giga per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.021</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Acute Phase</title>
        <time_frame>Week 0 and Week 10</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Acute Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>Units per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="434"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.25" spread="36.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.12" spread="20.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Acute Phase</title>
        <time_frame>Week 0 and Week 10</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Acute Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>actual count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.019</p_value>
            <p_value_desc>The mean change to endpoint of -0.00 indicates that on average, endpoint score decreased from baseline score by less than 0.005 units.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hemoglobin - Acute Phase</title>
        <time_frame>Week 0 and Week 10</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hemoglobin - Acute Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>millimoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.81" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.005</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Platelet Count - Acute Phase</title>
        <time_frame>Week 0 and Week 10</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Platelet Count - Acute Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>Giga per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.08" spread="60.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.23" spread="40.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.031</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Sodium - Acute Phase</title>
        <time_frame>Week 0 and Week 10</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Sodium - Acute Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>millimoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.21" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Acute Phase</title>
        <time_frame>Week 0 and Week 10</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Acute Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>grams per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.59" spread="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Uric Acid - Acute Phase</title>
        <time_frame>Week 0 and Week 10</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Uric Acid - Acute Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>micromoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297.05" spread="81.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.64" spread="49.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Albumin - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Albumin - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>grams per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.43" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bicarbonate, HCO3 - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bicarbonate, HCO3 - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>millimoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.41" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bilirubin, Direct - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bilirubin, Direct - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>micromoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.004</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bilirubin, Total - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bilirubin, Total - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>micromoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.68" spread="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.010</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>millimoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.003</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Erythrocyte Count - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Erythrocyte Count - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>Tera per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>Units per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.13" spread="24.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="17.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.015</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>Actual count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.021</p_value>
            <p_value_desc>The mean change to endpoint of -0.00 indicates that on average, endpoint score decreased from baseline score by less than 0.005 units.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hemoglobin - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hemoglobin - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>millimoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.73" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Leukocyte Count - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Leukocyte Count - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>Giga per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.40" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.032</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Low Density Lipoprotein (LDL) Cholesterol (Direct) - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Low Density Lipoprotein (LDL) Cholesterol (Direct) - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>millimoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Hemoglobin - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Hemoglobin - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>millimoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.73" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Volume (MCV) - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Volume (MCV) - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>femtoliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.33" spread="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.028</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Monocytes - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Monocytes - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>Giga per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.008</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Continuation Phase</title>
        <time_frame>Week 10 (baseline) and Week 34 (endpoint) (Continuation Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Continuation Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Continuation Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>grams per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.47" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.046</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test assesses if within treatment mean changes from baseline to endpoint are significantly different from zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Alanine Aminotransferase (ALT) - Maintenance Phase</title>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Alanine Aminotransferase (ALT) - Maintenance Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>Units per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.81" spread="11.56"/>
                    <measurement group_id="O2" value="22.12" spread="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="15.40"/>
                    <measurement group_id="O2" value="-0.38" spread="12.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>P-value for Change to Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Type II Sums of Squares from an analysis of variance (ANOVA) on the Ranks: Model = Pooled Investigator and Therapy.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Maintenance Phase</title>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Maintenance Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>millimoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="0.10"/>
                    <measurement group_id="O2" value="2.43" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.10"/>
                    <measurement group_id="O2" value="-0.01" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>P-value for Change to Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Type II Sums of Squares from an analysis of variance (ANOVA) on the Ranks: Model = Pooled Investigator and Therapy.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Glucose - Maintenance Phase</title>
        <time_frame>Week 34 (baseline) and Week 86 (endpoint) (Maintenance Phase)</time_frame>
        <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Glucose - Maintenance Phase</title>
          <population>Number of patients with a baseline and at least one non-missing post-baseline value. Intent to Treat analysis.</population>
          <units>millimoles per Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasting Glucose Baseline (N=120,N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.40" spread="0.72"/>
                    <measurement group_id="O2" value="5.47" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fasting Glucose Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.71"/>
                    <measurement group_id="O2" value="0.03" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Fasting Glucose Baseline (N=41,N=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68" spread="0.91"/>
                    <measurement group_id="O2" value="5.74" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Fasting Glucose Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="1.18"/>
                    <measurement group_id="O2" value="0.62" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.744</p_value>
            <p_value_desc>P-value for fasting glucose change from baseline to endpoint</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Type II Sums of Squares from an analysis of variance (ANOVA) on the Ranks: Model = Pooled Investigator and Therapy.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <p_value_desc>P-value for non-fasting glucose change from baseline to endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Type II Sums of Squares from an analysis of variance (ANOVA) on the Ranks: Model = Pooled Investigator and Therapy.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of Participants -- Open-Label Acute Therapy Phase</title>
        <time_frame>Every Visit from Week 0 up to Week 10 (Acute)</time_frame>
        <population>Treatment-Emergent Adverse Events (TEAE) occurring in at least 5% of patients. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Acute Phase</title>
            <description>duloxetine 60-120 mg every day (QD) from Week 0 (baseline) to Week 10 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of Participants -- Open-Label Acute Therapy Phase</title>
          <population>Treatment-Emergent Adverse Events (TEAE) occurring in at least 5% of patients. Intent to Treat analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with &gt;= 1 Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dry mouth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperhidrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of the Participants -- Open-Label Continuation Phase</title>
        <time_frame>Every Visit from Week 10 up to Week 34 (Continuation)</time_frame>
        <population>Treatment-Emergent Adverse Events (TEAE) occurring in at least 5% of patients. Intent to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg</title>
            <description>duloxetine 60 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 90 mg</title>
            <description>duloxetine 90 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 120 mg</title>
            <description>duloxetine 120 mg every day (QD) from Week 10 (baseline) to Week 34 (Endpoint)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of the Participants -- Open-Label Continuation Phase</title>
          <population>Treatment-Emergent Adverse Events (TEAE) occurring in at least 5% of patients. Intent to Treat analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with &gt;= 1 Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasopharyngitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperhidrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>Duloxetine 60 mg</title>
          <description>Duloxetine 60 mg</description>
        </group>
        <group group_id="E3">
          <title>Duloxetine 90 mg</title>
          <description>Duloxetine 90 mg</description>
        </group>
        <group group_id="E4">
          <title>Duloxetine 120 mg</title>
          <description>Duloxetine 120 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5"/>
                <counts group_id="E2" subjects_affected="5"/>
                <counts group_id="E3" subjects_affected="3"/>
                <counts group_id="E4" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Endocarditis staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pneumonia chlamydial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105"/>
                <counts group_id="E2" subjects_affected="51"/>
                <counts group_id="E3" subjects_affected="36"/>
                <counts group_id="E4" subjects_affected="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="142"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="142"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="142"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="142"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="142"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="18" subjects_at_risk="142"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="142"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="142"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="142"/>
                <counts group_id="E2" events="28" subjects_affected="21" subjects_at_risk="64"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E2" events="9" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="142"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ejaculation delayed</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="142"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="45"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>1-800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

